BACKGROUND: We have previously documented the finding that central angiotensin type 2 receptors (AT2R) negatively modulate sympathetic outflow and arterial blood pressure (BP). In this study, we investigated the effects of intracerebroventricular (icv) infusion of Compound 21 (C21), the first selective nonpeptide AT2R agonist, on norepinephrine (NE) excretion and BP in rats. METHODS: C21 was infused icv for 7 days, using a micro-osmotic pump. Urinary NE concentration was measured using the NE enzyme immunoassay kit. BP was recorded by radiotelemetry. After 7 days, the rats were killed and three relevant samples from sympathetic brain regions and the cerebral cortex were obtained by micro-punching to measure neuronal nitric oxide synthase (nNOS) protein expression by western blot. In addition, the influence of C21 on neuronal potassium current (I(Kv)) was determined by whole-cell patch-clamp in a neuron cell line, CATH.a. RESULTS: (i) Icv treatment with C21 significantly decreased both the concentration and the amount of NE in night time urine, but had no effect on daytime urine. (ii) C21-treated rats exhibited a slight but significant decrease in BP. (iii) The effects of C21 on NE excretion and BP were abolished by use of the AT2R antagonist, PD123319, and nitric oxide synthase (NOS) inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME). (iv) C21 treatment significantly upregulated nNOS expression in the paraventricular nucleus of the hypothalamus (PVN) and rostral ventrolateral medulla (RVLM), but not in the nucleus of the solitary tract (NTS) and cerebral cortex. (v) In CATH.a neurons, C21 treatment significantly increased I(Kv), and this increase was completely abolished by PD123319 and L-NAME. CONCLUSIONS: These results demonstrate a central inhibitory influence of C21 on sympathetic outflow by means of a nNOS-dependent mechanism that might be mediated by facilitating the neuronal potassium channel.
BACKGROUND: We have previously documented the finding that central angiotensin type 2 receptors (AT2R) negatively modulate sympathetic outflow and arterial blood pressure (BP). In this study, we investigated the effects of intracerebroventricular (icv) infusion of Compound 21 (C21), the first selective nonpeptide AT2R agonist, on norepinephrine (NE) excretion and BP in rats. METHODS: C21 was infused icv for 7 days, using a micro-osmotic pump. Urinary NE concentration was measured using the NE enzyme immunoassay kit. BP was recorded by radiotelemetry. After 7 days, the rats were killed and three relevant samples from sympathetic brain regions and the cerebral cortex were obtained by micro-punching to measure neuronal nitric oxide synthase (nNOS) protein expression by western blot. In addition, the influence of C21 on neuronal potassium current (I(Kv)) was determined by whole-cell patch-clamp in a neuron cell line, CATH.a. RESULTS: (i) Icv treatment with C21 significantly decreased both the concentration and the amount of NE in night time urine, but had no effect on daytime urine. (ii) C21-treated rats exhibited a slight but significant decrease in BP. (iii) The effects of C21 on NE excretion and BP were abolished by use of the AT2R antagonist, PD123319, and nitric oxide synthase (NOS) inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME). (iv) C21 treatment significantly upregulated nNOS expression in the paraventricular nucleus of the hypothalamus (PVN) and rostral ventrolateral medulla (RVLM), but not in the nucleus of the solitary tract (NTS) and cerebral cortex. (v) In CATH.a neurons, C21 treatment significantly increased I(Kv), and this increase was completely abolished by PD123319 and L-NAME. CONCLUSIONS: These results demonstrate a central inhibitory influence of C21 on sympathetic outflow by means of a nNOS-dependent mechanism that might be mediated by facilitating the neuronal potassium channel.
Authors: Elena Kaschina; Aleksandra Grzesiak; Jun Li; Anna Foryst-Ludwig; Melanie Timm; Franziska Rompe; Manuela Sommerfeld; U Rudolf Kemnitz; Caterina Curato; Pawel Namsolleck; Carsten Tschöpe; Anders Hallberg; Mathias Alterman; Thomas Hucko; Ingo Paetsch; Thore Dietrich; Bernhard Schnackenburg; Kristof Graf; Björn Dahlöf; Ulrich Kintscher; Thomas Unger; U Muscha Steckelings Journal: Circulation Date: 2008-11-24 Impact factor: 29.690
Authors: Gang Wang; Christal G Coleman; Michael J Glass; Ping Zhou; Qi Yu; Laibaik Park; Josef Anrather; Virginia M Pickel; Costantino Iadecola Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-02-29 Impact factor: 3.619
Authors: Gilbert Moralez; Noah P Jouett; Jun Tian; Matthew C Zimmerman; Paul Bhella; Peter B Raven Journal: J Physiol Date: 2018-05-15 Impact factor: 5.182
Authors: Colin Sumners; Amy Alleyne; Vermalí Rodríguez; David J Pioquinto; Jacob A Ludin; Shormista Kar; Zachary Winder; Yuma Ortiz; Meng Liu; Eric G Krause; Annette D de Kloet Journal: Hypertens Res Date: 2019-12-18 Impact factor: 3.872